BACLOPAR Tablets 25 Milligram
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
19-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
BACLOFEN
Available from:
Generics (UK) Limited
Dosage:
25 Milligram
Pharmaceutical form:
Tablets
Authorization date:
1989-11-21
Summary of Product characteristics
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Baclopar 25 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 25 mg of Baclofen
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Tablet
A white tablet, marked “BN” breakline “25” on
one side and “G” on the reverse.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
4.1.1
Relief of voluntary muscle spasticity as occurs in
conditions such as multiple sclerosis and spinal cord
lesions including syringomelia, transverse myelitis and
motor neurone disease.
4.1.2
Management of spasticity of cerebral origin including meningitis,
cerebral palsy, traumatic head injury,
cerebrovascular accident.
Baclofen is of most benefit in relief of spasticity which
is seriously interfering with activity.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
For oral administration only.
Relief of voluntary muscle spasticity in spinal cord lesions and
management of spasticity of cerebral origin.
_ADULTS: _A gradually increasing dosage regimen of baclofen
is recommended which should be adjusted to
achieve satisfactory symptom control.
5mg three times a day for three days
10mg three times a day for three days
15mg three times a day for three days
20mg three times a day for three days
25mg three times a day for three days
Symptoms are usually adequately controlled with doses up to 60mg
daily. However, in order to meet
individual patient needs, dosage adjustments should
be slow and careful. The dose should not exceed 100mg
per day unless the patient is in
hospital under medical supervision. If therapeutic effect is not achieved
within
6 weeks of reaching the maximum recommended dose, a decision
of whether to continue with therapy should
be taken. In some cases, mobility is improved with
small frequent doses, especially if given 1 hour prior to
performing manual task
Read the complete document
